Beam Therapeutics第三季度每股收益$（1.10）错过$（1.05）估计，销售额969.8万美元错过1236.8万美元估计

Beam Therapeutics (NASDAQ: BEAM) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.05) by 5.16 percent. This is a 5.98 percent increase over losses of $(1.17) per share from the same period last year. The company reported quarterly sales of $9.698 million which missed the analyst consensus estimate of $12.368 million by 21.59 percent. This is a 32.03 percent decrease over sales of $14.269 million the same period last year.